Publications | National Cancer Centre Singapore

Toh HC, Yang MH, Wang HM, Hsieh CY, Chitapanarux I, Ho KF, Hong RL, Ang MK, Colevas AD, Sirachainan E, Lertbutsayanukul C, Ho GF, Nadler E, Algazi A, Lulla P, Wirth LJ, Wirasorn K, Liu YC, Ang SF, Low SHJ, Tho LM, Hasbullah HH, Brenner MK, Wang WW, Ong WS, Tan SH, Horak I, Ding C, Myo A, Samol J. Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Ann Oncol. 2024 Dec;35(12):1181-1190. doi: 10.1016/j.annonc.2024.08.2344. Epub 2024 Sep 4. PMID: 39241963.
Chia JW K *, Segelov E*, Deng Y, Ho GF, Wang W, Han S, Sharma A, Ding K, Chen G, Jeffery M, Tham CK, Ahn JB, Nott L, Zielinski R, Chao T-Y, Hagen TV, Wei PL, Day F, Mehta S, Yau T, Peng J, Hayes TM, Li Y, Gandhi M, Foo EMJ, Rahman N, Rothwell P, Ali R, Simes J, Toh HC. Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial. Accepted in The Lancet Gastroenterology & Hepatology.
Kim HD, Jung S, Lim HY, Ryoo BY, Ryu MH, Chuah S, Chon HJ, Kang B, Hong JY, Lee HC, Moon DB, Kim KH, Kim TW, Tai D, Chew V, Lee JS, Finn RS, Koh JY, Yoo C. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat Med. 2024 Mar;30(3):699-707. doi: 10.1038/s41591-024-02824-y. Epub 2024 Feb 19. PMID: 38374347; PMCID: PMC10957471.
Xu H, Fu H, Long Y, Ang KS, Sethi R, Chong K, Li M, Uddamvathanak R, Lee HK, Ling J, Chen A, Shao L, Liu L, Chen J. Unsupervised spatially embedded deep representation of spatial transcriptomics. Genome Med. 2024 Jan 12;16(1):12. doi: 10.1186/s13073-024-01283-x. PMID: 38217035; PMCID: PMC10790257.
Chew V, Chuang CH, Hsu C. Translational research on drug development and biomarker discovery for hepatocellular carcinoma. J Biomed Sci. 2024 Feb 17;31(1):22. doi: 10.1186/s12929-024-01011-y. PMID: 38368324; PMCID: PMC10874078.
Ma S, Chew V. Unlocking the immune microenvironment of nonalcoholic steatohepatitis-associated HCC. Hepatology. 2024 Mar 1;79(3):532-534. doi: 10.1097/HEP.0000000000000626. Epub 2023 Oct 9. PMID: 37812454.
Lee YF, Chen L, Chew V, Chow EK, Deng LW, Hunziker W, Lee ASG, Leong G, Ngeow J, Pervaiz S, Sabapathy K, Skanderup AJ, Sundar R, Tay Y, Virshup DM, Wong SH, Tergaonkar V, Tam WL. Pushing the Frontiers of Cancer Research: Highlights from the Frontiers in Cancer Science Conference 2023. Cancer Res. 2024 Apr 15;84(8):1195-1198. doi: 10.1158/0008-5472.CAN-24-0721. PMID: 38616656.
Yeo BSY, Lee RS, Lim NE, Tan E, Jang IJH, Toh HC, Lim CM. Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis. Oral Oncol. 2024 May;152:106786. doi: 10.1016/j.oraloncology.2024.106786. Epub 2024 Apr 13. PMID: 38615584.
Liu X, Zhang K, Kaya NA, Jia Z, Wu D, Chen T, Liu Z, Zhu S, Hillmer AM, Wuestefeld T, Liu J, Chan YS, Hu Z, Ma L, Jiang L, Zhai W. Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in Hepatocellular Carcinoma. Nat Commun. 2024 Apr 12;15(1):3169. doi: 10.1038/s41467-024-47541-9. PMID: 38609353; PMCID: PMC11015015.
Yeo BSY, Song HJJMD, Soong YL, Chua MLK, Ang MK, Lim DWT, See A, Lim CM. Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis. Oral Oncol. 2023 2Jan;136:106242. doi: 10.1016/j.oraloncology.2022.106242. Epub 2022 Nov 19. PMID: 36413976.
Yeo XY, Tan LY, Chae WR, Lee DY, Lee YA, Wuestefeld T, Jung S. Liver's influence on the brain through the action of bile acids. Front Neurosci. 2023 Feb 2;17:1123967. doi: 10.3389/fnins.2023.1123967. PMID: 36816113; PMCID: PMC9932919.
Wuestefeld A, Iakovleva V, Yap SXL, Ong ABL, Huang DQ, Shuen TWH, Toh HC, Dan YY, Zender L, Wuestefeld T. A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes. Cancer Res. 2023 Feb 3;83(3):428-440. doi: 10.1158/0008-5472.CAN-22-1477. PMID: 36449018; PMCID: PMC9896023.
Wu L, Brzostek J, Sakthi Vale PD, Wei Q, Koh CKT, Ong JXH, Wu LZ, Tan JC, Chua YL, Yap J, Song Y, Tan VJY, Tan TYY, Lai J, MacAry PA, Gascoigne NRJ. CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. Cell Rep Med. 2023 Feb 21;4(2):100917. doi: 10.1016/j.xcrm.2023.100917. Epub 2023 Jan 24. PMID: 36696897; PMCID: PMC9975250.
Long Y, Ang KS, Li M, Chong KLK, Sethi R, Zhong C, Xu H, Ong Z, Sachaphibulkij K, Chen A, Zeng L, Fu H, Wu M, Lim LHK, Liu L, Chen J. Spatially informed clustering, integration, and deconvolution of spatial transcriptomics with GraphST. Nat Commun. 2023 Mar 1;14(1):1155. doi: 10.1038/s41467-023-36796-3. PMID: 36859400; PMCID: PMC9977836.
Lim DW, Kao HF, Suteja L, Li CH, Quah HS, Tan DS, Tan SH, Tan EH, Tan WL, Lee JN, Wee FY, Jain A, Goh BC, Chua MLK, Liao BC, Ng QS, Hong RL, Ang MK, Yeong JP, Iyer NG. Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma. Nat Commun. 2023 May 15;14(1):2781. doi: 10.1038/s41467-023-38407-7. PMID: 37188668; PMCID: PMC10184620.
Ng JWK, Tan KW, Guo DY, Lai JJH, Fan X, Poon Z, Lim TH, Lim AST, Lim TKH, Hwang WYK, Li S, Eaves CJ, Goh YT, Cheung AMS. Cord blood-derived Vδ2+ and Vδ2- T cells acquire differential cell state compositions upon in vitro expansion. Sci Adv. 2023 Jun 16;9(24):eadf3120. doi: 10.1126/sciadv.adf3120. Epub 2023 Jun 16. PMID: 37327346; PMCID: PMC10275585.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators including Toh HC. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. PMID: 37871608.
Chew V. Unveiling the hidden battlefield: dissecting the invasive zone in liver cancer. Cell Res. 2023 Sep;33(9):651-652. doi: 10.1038/s41422-023-00855-7. PMID: 37488306; PMCID: PMC10474255.
Lee YH, Chuah S, Nguyen PHD, Lim CJ, Lai HLH, Wasser M, Chua C, Lim TKH, Leow WQ, Loh TJ, Wan WK, Pang YH, Soon G, Cheow PC, Kam JH, Iyer S, Kow A, Bonney GK, Chan CY, Chung A, Goh BKP, Zhai W, Chow PKH, Albani S, Liu H, Chew V. IFNγ-IL-17+ CD8 T cells contribute to immunosuppression and tumor progression in human hepatocellular carcinoma. Cancer Lett. 2023 Jan 1;552:215977. doi: 10.1016/j.canlet.2022.215977. Epub 2022 Oct 21. PMID: 36279983.
Lee NYS, Li M, Ang KS, Chen J. Establishing a human bone marrow single cell reference atlas to study ageing and diseases. Front Immunol. 2023 Mar 15;14:1127879. doi: 10.3389/fimmu.2023.1127879. PMID: 37006302; PMCID: PMC10050687.
Zhao J, Lee K, Toh HC, Lam KP, Neo SY. Unravelling the role of obesity and lipids during tumor progression. Front Pharmacol. 2023 Mar 30;14:1163160. doi: 10.3389/fphar.2023.1163160. PMID: 37063269; PMCID: PMC10097918.
Zhao J, Fong A, Seow SV, Toh HC. Organoids as an Enabler of Precision Immuno-Oncology. Cells. 2023 Apr 14;12(8):1165. doi: 10.3390/cells12081165. PMID: 37190074; PMCID: PMC10136954.
Cheung CCL, Seah YHJ, Fang J, Orpilla NHC, Lau MC, Lim CJ, Lim X, Lee JNLW, Lim JCT, Lim S, Cheng Q, Toh HC, Choo SP, Lee SY, Lee JJX, Liu J, Lim TKH, Tai D, Yeong J. Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma. Front Immunol. 2023 Jun 5;14:1150985. doi: 10.3389/fimmu.2023.1150985. PMID: 37342338; PMCID: PMC10277502.
Kaya NA, Tai D, Lim X, Lim JQ, Lau MC, Goh D, Phua CZJ, Wee FYT, Joseph CR, Lim JCT, Neo ZW, Ye J, Cheung L, Lee J, Loke KSH, Gogna A, Yao F, Lee MY, Shuen TWH, Toh HC, Hilmer A, Chan YS, Lim TK, Tam WL, Choo SP, Yeong J, Zhai W. Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma. J Immunother Cancer. 2023 Aug;11(8):e007106. doi: 10.1136/jitc-2023-007106. PMID: 37586766; PMCID: PMC10432632.
Low YH, Loh CJL, Peh DYY, Chu AJM, Han S, Toh HC. Pathogenesis and therapeutic implications of EBV-associated epithelial cancers. Front Oncol. 2023 Oct 2;13:1202117. doi: 10.3389/fonc.2023.1202117. PMID: 37901329; PMCID: PMC10600384.
Meng J, Tan JYT, Joseph CR, Ye J, Lim JCT, Goh D, Xue Y, Lim X, Koh VCY, Wee F, Tay TKY, Chan JY, Ng CCY, Iqbal J, Lau MC, Lim HE, Toh HC, Teh BT, Dent RA, Tan PH, Yeong JPS. The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women. Lab Invest. 2024 Mar;104(3):100303. doi: 10.1016/j.labinv.2023.100303. Epub 2023 Dec 14. PMID: 38103870.
Wong EYT, Lee JWJ, Lim JFY, Toh HC. The East Asian gut microbiome and its role in oncology: a narrative review. Singapore Med J. 2023 Jun 1. doi: 10.4103/singaporemedj.SMJ-2022-042. Epub ahead of print. PMID: 37338497.
Wong EYT, Lim JFY, Toh HC. A review on paying for advanced cancer therapeutics: hard truths and realities in Asia. Chin Clin Oncol. 2023 Aug;12(4):40. doi: 10.21037/cco-23-37. Epub 2023 Jul 31. PMID: 37574569.
Zheng S, Chan SW, Liu F, Liu J, Chow PKH, Toh HC, Hong W. Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges. Cancers (Basel). 2024 Apr 20;16(8):1582. doi: 10.3390/cancers16081582. PMID: 38672664; PMCID: PMC11048862.
Neo SY, Xu S, Chong J, Lam KP, Wu J. Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer. J Immunother Cancer. 2023 Apr;11(4):e006434. doi: 10.1136/jitc-2022-006434. PMID: 37100458; PMCID: PMC10151952.
Reolo MJY, Otsuka M, Seow JJW, Lee J, Lee YH, Nguyen PHD, Lim CJ, Wasser M, Chua C, Lim TKH, Leow WQ, Chung A, Goh BKP, Chow PKH, DasGupta R, Yeong JPS, Chew V. CD38 marks the exhausted CD8+ tissue-resident memory T cells in hepatocellular carcinoma. Front Immunol. 2023 Jun 12;14:1182016. doi: 10.3389/fimmu.2023.1182016. PMID: 37377962; PMCID: PMC10292929.
Hora S, Wuestefeld T. Liver Injury and Regeneration: Current Understanding, New Approaches, and Future Perspectives. Cells. 2023 Aug 22;12(17):2129. doi: 10.3390/cells12172129. PMID: 37681858; PMCID: PMC10486351.
Nguyen PHD, Wasser M, Tan CT, Lim CJ, Lai HLH, Seow JJW, DasGupta R, Phua CZJ, Ma S, Yang J, Suthen SD, Tam WL, Lim TKH, Yeong J, Leow WQ, Pang YH, Soon G, Loh TJ, Wan WK, Chan CY, Cheow PC, Toh HC, Kow A, Dan YY, Kam JH, Iyer S, Madhavan K, Chung A, Bonney GK, Goh BKP, Fu N, Yu VC, Zhai W, Albani S, Chow PKH, Chew V. Trajectory of immune evasion and cancer progression in hepatocellular carcinoma. Nat Commun. 2022 Mar 17;13(1):1441. doi: 10.1038/s41467-022-29122-w. PMID: 35301339; PMCID: PMC8931110.
Li M, Zhang X, Ang KS, Ling J, Sethi R, Lee NYS, Ginhoux F, Chen J. DISCO: a database of Deeply Integrated human Single-Cell Omics data. Nucleic Acids Res. 2022 Jan 7;50(D1):D596-D602. doi: 10.1093/nar/gkab1020. PMID: 34791375; PMCID: PMC8728243.
Chuah S, Lee J, Song Y, Kim HD, Wasser M, Kaya NA, Bang K, Lee YJ, Jeon SH, Suthen S, A'Azman S, Gien G, Lim CJ, Chua C, Hazirah SN, Lee HK, Lim JQ, Lim TKH, Yeong J, Chen J, Shin EC, Albani S, Zhai W, Yoo C, Liu H, Choo SP, Tai D, Chew V. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. J Hepatol. 2022 Sep;77(3):683-694. doi: 10.1016/j.jhep.2022.03.039. Epub 2022 Apr 15. PMID: 35430299.
Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. PMID: 35739268.
Kaya NA, Chen J, Lai H, Yang H, Ma L, Liu X, Alvarez JS, Liu J, Hillmer AM, Tai D, Sheng JYP, Hu Z, Chan YS, Chow PKH, Mu Y, Wuestefeld T, Zhai W. Genome instability is associated with ethnic differences between Asians and Europeans in hepatocellular carcinoma. Theranostics. 2022 Jun 6;12(10):4703-4717. doi: 10.7150/thno.71676. PMID: 35832070; PMCID: PMC9254249.
Nickles E, Dharmadhikari B, Yating L, Walsh RJ, Koh LP, Poon M, Tan LK, Wang LZ, Ang Y, Asokumaran Y, Chong WQ, Huang Y, Loh KS, Tay J, Soo R, Koh M, Ho LP, Chan M, Niam M, Soh M, Luah YH, Lim CM, Kaliaperumal N, Au VB, Talib NBSN, Sng R, Connolly JE, Goh BC, Schwarz H. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit. Cancer Immunol Immunother. 2022 Jun;71(6):1531-1543. doi: 10.1007/s00262-021-03075-3. Epub 2021 Oct 18. PMID: 34661709; PMCID: PMC10991364.
Li D, Toh HC, Merle P, Tsuchiya K, Hernandez S, Verret W, Nicholas A, Kudo M. Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. Liver Cancer. 2022 Jul 13;11(6):558-571. doi: 10.1159/000525671. PMID: 36589722; PMCID: PMC9801180.
Shuen TWH, Alunni-Fabbroni M, Öcal E, Malfertheiner P, Wildgruber M, Schinner R, Pech M, Benckert J, Sangro B, Kuhl C, Gasbarrini A, Chow PKH, Toh HC, Ricke J. Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial. Clin Cancer Res. 2022 Sep 1;28(17):3890-3901. doi: 10.1158/1078-0432.CCR-22-0569. PMID: 35763041; PMCID: PMC9433961.
Tan TJ, Ang WXG, Wang WW, Chong HS, Tan SH, Cheong R, Chia JW, Syn NL, Shuen WH, Ba R, Kaliaperumal N, Au B, Hopkins R, Li X, Tan AC, Seet AOL, Connolly JE, Arkachaisri T, Chew V, Lajam ABM, Guo D, Chew MZW, Wasser M, Kumar P, Albani S, Toh HC. A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma. Nat Commun. 2022 Oct 28;13(1):6453. doi: 10.1038/s41467-022-33834-4. PMID: 36307410; PMCID: PMC9616917.
Suthen S, Lim CJ, Nguyen PHD, Dutertre CA, Lai HLH, Wasser M, Chua C, Lim TKH, Leow WQ, Loh TJ, Wan WK, Pang YH, Soon G, Cheow PC, Kam JH, Iyer S, Kow A, Tam WL, Shuen TWH, Toh HC, Dan YY, Bonney GK, Chan CY, Chung A, Goh BKP, Zhai W, Ginhoux F, Chow PKH, Albani S, Chew V. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC. Hepatology. 2022 Nov;76(5):1329-1344. doi: 10.1002/hep.32419. Epub 2022 Mar 17. PMID: 35184329.
Ding Z, Ericksen RE, Lee QY, Han W. Reprogramming of mitochondrial proline metabolism promotes liver tumorigenesis. Amino Acids. 2021 Dec;53(12):1807-1815. doi: 10.1007/s00726-021-02961-5. Epub 2021 Feb 28. PMID: 33646427.
Prasad M, Ponnalagu S, Zeng Q, Luu K, Lang SM, Wong HY, Cheng MS, Wu M, Mallilankaraman K, Sobota RM, Lim YT, Wang LC, Goh CK, Tay KXJ, Loh KS, Wang CI, Lee WH, Goh BC, Lim CM, Schwarz H. Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors. Cancer Immunol Immunother. 2022 Nov;71(11):2583-2596. doi: 10.1007/s00262-022-03183-8. Epub 2022 Mar 17. PMID: 35299256; PMCID: PMC10992239.
Chen S, Bin Abdul Rahim AA, Wang WW, Cheong R, Prabhu AV, Tan JZY, Naing MW, Toh HC, Liu D. In-situ scalable manufacturing of Epstein-Barr virus-specific T-cells using bioreactor with an expandable culture area (BECA). Sci Rep. 2022 Apr 29;12(1):7045. doi: 10.1038/s41598-022-11015-z. PMID: 35487951; PMCID: PMC9054749.
Tan AH, Cheung AMS, Kabelitz D. Editorial: Next generation γδ T cell-based tumor immunotherapy. Front Immunol. 2022 Sep 30;13:1041362. doi: 10.3389/fimmu.2022.1041362. PMID: 36248869; PMCID: PMC9562770.
Guerrero A, Innes AJ, Roux PF, Buisman SC, Jung J, Ortet L, Moiseeva V, Wagner V, Robinson L, Ausema A, Potapova A, Perdiguero E, Weersing E, Aarts M, Martin N, Wuestefeld T, Muñoz-Cánoves P, de Haan G, Bischof O, Gil J. 3-deazaadenosine (3DA) alleviates senescence to promote cellular fitness and cell therapy efficiency in mice. Nat Aging. 2022 Sep;2:851-866. doi: 10.1038/s43587-022-00279-9. Epub 2022 Sep 13. PMID: 36438588; PMCID: PMC7613850.
Kaseb AO, Guan Y, Gok Yavuz B, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y. Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2022 Oct 11;9:1065-1079. doi: 10.2147/JHC.S369951. PMID: 36254201; PMCID: PMC9569161.
Nickles E, Dharmadhikari B, Yating L, Walsh RJ, Koh LP, Poon M, Tan LK, Wang LZ, Ang Y, Asokumaran Y, Chong WQ, Huang Y, Loh KS, Tay J, Soo R, Koh M, Ho LP, Chan M, Niam M, Soh M, Luah YH, Lim CM, Kaliaperumal N, Au VB, Talib NBSN, Sng R, Connolly JE, Goh BC, Schwarz H. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit. Cancer Immunol Immunother. 2022 Jun;71(6):1531-1543. doi: 10.1007/s00262-021-03075-3. Epub 2021 Oct 18. PMID: 34661709; PMCID: PMC10991364.
Nguyen PHD, Ma S, Phua CZJ, Kaya NA, Lai HLH, Lim CJ, Lim JQ, Wasser M, Lai L, Tam WL, Lim TKH, Wan WK, Loh T, Leow WQ, Pang YH, Chan CY, Lee SY, Cheow PC, Toh HC, Ginhoux F, Iyer S, Kow AWC, Young Dan Y, Chung A, Bonney GK, Goh BKP, Albani S, Chow PKH, Zhai W, Chew V. Author Correction: Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nat Commun. 2021 Feb 23;12(1):1372. doi: 10.1038/s41467-021-21556-y. Erratum for: Nat Commun. 2021 Jan 11;12(1):227. doi: 10.1038/s41467-020-20171-7. PMID: 33623020; PMCID: PMC7902808.
Hopkins R, Xiang W, Marlier D, Au VB, Ching Q, Wu LX, Guan R, Lee B, Chia WK, Wang WW, Wee J, Ng J, Cheong R, Han S, Chu A, Chee CL, Shuen T, Podinger M, Lezhava A, Toh HC, Connolly JE. Monocytic Myeloid-Derived Suppressor Cells Underpin Resistance to Adoptive T Cell Therapy in Nasopharyngeal Carcinoma. Mol Ther. 2021 Feb 3;29(2):734-743. doi: 10.1016/j.ymthe.2020.09.040. Epub 2020 Sep 30. PMID: 33038324; PMCID: PMC7854281.
Zhao Y, Wang J, Liu WN, Fong SY, Shuen TWH, Liu M, Harden S, Tan SY, Cheng JY, Tan WWS, Chan JKY, Chee CE, Lee GH, Toh HC, Lim SG, Wan Y, Chen Q. Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model. Hepatology. 2021 Sep;74(3):1395-1410. doi: 10.1002/hep.31812. PMID: 33738839; PMCID: PMC9540409.
Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, Too CW, Ng MCH, Tham CK, Lam J, Koo SL, Chong HS, Goh GB, Huang HL, Venkatanarasimha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim TKH, Yeong J, Zhai W, Chan CY, Choo SP. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1025-1035. doi: 10.1016/S2468-1253(21)00305-8. Epub 2021 Oct 23. PMID: 34695377.
Zhai W, Lai H, Kaya NA, Chen J, Yang H, Lu B, Lim JQ, Ma S, Chew SC, Chua KP, Alvarez JJS, Chen PJ, Chang MM, Wu L, Goh BKP, Chung AY, Chan CY, Cheow PC, Lee SY, Kam JH, Kow AW, Ganpathi IS, Chanwat R, Thammasiri J, Yoong BK, Ong DB, de Villa VH, Dela Cruz RD, Loh TJ, Wan WK, Zeng Z, Skanderup AJ, Pang YH, Madhavan K, Lim TK, Bonney G, Leow WQ, Chew V, Dan YY, Tam WL, Toh HC, Foo RS, Chow PK. Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. Natl Sci Rev. 2021 Oct 29;9(3):nwab192. doi: 10.1093/nsr/nwab192. PMID: 35382356; PMCID: PMC8973408.
Lai F, Wee CYY, Chen Q. Establishment of Humanized Mice for the Study of HBV. Front Immunol. 2021 Feb 19;12:638447. doi: 10.3389/fimmu.2021.638447. PMID: 33679796; PMCID: PMC7933441.
Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, Tai D, Choo SP, Goh BKP, Yan SX, Loke KSH, Thang SP, Gogna A, Venkatanarasimha NK, Tong AKT, Moe FNN, Chua JSS, Ang RWT, Ong AD, Ng AWY, Hoang MTQ, Too CW, Thng CH, Chan WY, Kee W, Chan JHM, Irani F, Leong S, Lim KH, Wang MLC, Chow PKH. Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. Liver Cancer. 2021 Jun;10(3):224-239. doi: 10.1159/000514400. Epub 2021 Apr 7. PMID: 34239809; PMCID: PMC8237792.
Wang G, Mudgal P, Wang L, Shuen TWH, Wu H, Alexander PB, Wang WW, Wan Y, Toh HC, Wang XF, Li QJ. TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma. Oncoimmunology. 2021 Aug 2;10(1):1955545. doi: 10.1080/2162402X.2021.1955545. PMID: 34377592; PMCID: PMC8331028.
Han S, Tay JK, Loh CJL, Chu AJM, Yeong JPS, Lim CM, Toh HC. Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies. Front Immunol. 2021 Dec 10;12:734293. doi: 10.3389/fimmu.2021.734293. PMID: 34956172; PMCID: PMC8702733.
Wu L, Brzostek J, Sankaran S, Wei Q, Yap J, Tan TYY, Lai J, MacAry PA, Gascoigne NRJ. Targeting CAR to the Peptide-MHC Complex Reveals Distinct Signaling Compared to That of TCR in a Jurkat T Cell Model. Cancers (Basel). 2021 Feb 18;13(4):867. doi: 10.3390/cancers13040867. PMID: 33670734; PMCID: PMC7922477.
Suter MA, Tan NY, Thiam CH, Khatoo M, MacAry PA, Angeli V, Gasser S, Zhang YL. cGAS-STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells. Sci Rep. 2021 Mar 31;11(1):7243. doi: 10.1038/s41598-021-86644-x. PMID: 33790360; PMCID: PMC8012641.
Banik D, Hamidinia M, Brzostek J, Wu L, Stephens HM, MacAry PA, Reinherz EL, Gascoigne NRJ, Lang MJ. Single Molecule Force Spectroscopy Reveals Distinctions in Key Biophysical Parameters of αβ T-Cell Receptors Compared with Chimeric Antigen Receptors Directed at the Same Ligand. J Phys Chem Lett. 2021 Aug 12;12(31):7566-7573. doi: 10.1021/acs.jpclett.1c02240. Epub 2021 Aug 4. PMID: 34347491; PMCID: PMC9082930.
Lim CJ, Chew V. Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma. Semin Liver Dis. 2020 May;40(2):131-142. doi: 10.1055/s-0039-3399534. Epub 2019 Dec 6. PMID: 31810095.
Kong LR, Mohamed Salleh NAB, Ong RW, Tan TZ, Syn NL, Goh RM, Fhu CW, Tan DSW, Iyer NG, Kannan S, Verma CS, Lim YC, Soo R, Ho J, Huang Y, Lim JSJ, Yan BJ, Nga ME, Lim SG, Koeffler HP, Lee SC, Kappei D, Hung HT, Goh BC. A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma. Nat Commun. 2020 Mar 25;11(1):1556. doi: 10.1038/s41467-020-15318-5. PMID: 32214092; PMCID: PMC7096530.
Ho LP, Teo Bryan YW, Linn YC, Tan PH, Jabed I, Toh HC, Yeoh KW. Unifying framework for acute resolution, malignancy and autoimmunity. Scand J Immunol. 2020 May;91(5):e12869. doi: 10.1111/sji.12869. Epub 2020 Feb 21. PMID: 32017146.
Chuah S, Chew V. High-dimensional immune-profiling in cancer: implications for immunotherapy. J Immunother Cancer. 2020 Feb;8(1):e000363. doi: 10.1136/jitc-2019-000363. PMID: 32034066; PMCID: PMC7057482.
Liu WN, Fong SY, Tan WWS, Tan SY, Liu M, Cheng JY, Lim S, Suteja L, Huang EK, Chan JKY, Iyer NG, Yeong JPS, Lim DW, Chen Q. Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy. Cancers (Basel). 2020 Apr 22;12(4):1025. doi: 10.3390/cancers12041025. PMID: 32331230; PMCID: PMC7225949.
Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2021 Feb;28(1-2):5-17. doi: 10.1038/s41417-020-0183-x. Epub 2020 May 27. PMID: 32457487; PMCID: PMC7886651.
Ang WX, Ng YY, Xiao L, Chen C, Li Z, Chi Z, Tay JC, Tan WK, Zeng J, Toh HC, Wang S. Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts. Mol Ther Oncolytics. 2020 May 4;17:421-430. doi: 10.1016/j.omto.2020.04.013. PMID: 32462079; PMCID: PMC7240063.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators including Toh HC. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. PMID: 32402160.
Ahl PJ, Hopkins RA, Xiang WW, Au B, Kaliaperumal N, Fairhurst AM, Connolly JE. Met-Flow, a strategy for single-cell metabolic analysis highlights dynamic changes in immune subpopulations. Commun Biol. 2020 Jun 12;3(1):305. doi: 10.1038/s42003-020-1027-9. PMID: 32533056; PMCID: PMC7292829.
Li LJ, Chong Q, Wang L, Goh BC, Soo RA. Different treatment efficacies and side effects of cytotoxic chemotherapy. J Thorac Dis. 2020 Jul;12(7):3785-3795. doi: 10.21037/jtd.2019.08.63. PMID: 32802458; PMCID: PMC7399437.
Chong YC, Toh TB, Chan Z, Lin QXX, Thng DKH, Hooi L, Ding Z, Shuen T, Toh HC, Dan YY, Bonney GK, Zhou L, Chow P, Wang Y, Benoukraf T, Chow EK, Han W. Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression. Hepatol Commun. 2020 Jul 27;4(9):1362-1381. doi: 10.1002/hep4.1559. PMID: 32923839; PMCID: PMC7471427.
Liou AK, Soon G, Tan L, Peng Y, Cher BM, Goh BC, Wang S, Lim CM. Elevated IL18 levels in Nasopharyngeal carcinoma induced PD-1 expression on NK cells in TILS leading to poor prognosis. Oral Oncol. 2020 May;104:104616. doi: 10.1016/j.oraloncology.2020.104616. Epub 2020 Mar 6. PMID: 32151994.
Sharma A, Seow JJW, Dutertre CA, Pai R, Blériot C, Mishra A, Wong RMM, Singh GSN, Sudhagar S, Khalilnezhad S, Erdal S, Teo HM, Khalilnezhad A, Chakarov S, Lim TKH, Fui ACY, Chieh AKW, Chung CP, Bonney GK, Goh BK, Chan JKY, Chow PKH, Ginhoux F, DasGupta R. Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell. 2020 Oct 15;183(2):377-394.e21. doi: 10.1016/j.cell.2020.08.040. Epub 2020 Sep 24. PMID: 32976798.
Chong WQ, Lim CM, Sinha AK, Tan CS, Chan GHJ, Huang Y, Kumarakulasinghe NB, Sundar R, Jeyasekharan AD, Loh WS, Tay JK, Yadav K, Wang L, Wong AL, Kong LR, Soo RA, Lau JA, Soon YY, Goh RM, Ho FCH, Chong SM, Lee SC, Loh KS, Tai BC, Lim YC, Goh BC. Integration of blockade Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. Clin Cancer Res. 2020 Oct 15;26(20):5320-5328. doi: 10.1158/1078-0432.CCR-20-1727. Epub 2020 Aug 14. PMID: 32816944.
Han S, Shuen WH, Wang WW, Nazim E, Toh HC. Tailoring precision immunotherapy: coming to a clinic soon? ESMO Open. 2020;5 Suppl 1(Suppl 1):e000631. doi: 10.1136/esmoopen-2019-000631. Epub 2020 Sep 30. PMID: 33558033; PMCID: PMC7046383.
Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Front Immunol. 2020 Sep 30;11:568759. doi: 10.3389/fimmu.2020.568759. PMID: 33117354; PMCID: PMC7561368.
Li J, Eu JQ, Kong LR, Wang L, Lim YC, Goh BC, Wong ALA. Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. Molecules. 2020 Oct 20;25(20):4831. doi: 10.3390/molecules25204831. PMID: 33092283; PMCID: PMC7588013.
Han S, Lee SY, Wang WW, Tan YB, Sim RHZ, Cheong R, Tan C, Hopkins R, Connolly J, Shuen WH, Toh HC. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs). Cancers (Basel). 2020 Nov 17;12(11):3404. doi: 10.3390/cancers12113404. PMID: 33212880; PMCID: PMC7698436.
Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2020 Aug;8(2):e000987. doi: 10.1136/jitc-2020-000987. PMID: 32847986; PMCID: PMC7451957.
Lim CJ, Lee YH, Pan L, Lai L, Chua C, Wasser M, Lim TKH, Yeong J, Toh HC, Lee SY, Chan CY, Goh BK, Chung A, Heikenwälder M, Ng IO, Chow P, Albani S, Chew V. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019 May;68(5):916-927. doi: 10.1136/gutjnl-2018-316510. Epub 2018 Jul 3. PMID: 29970455.
Ericksen RE, Lim SL, McDonnell E, Shuen WH, Vadiveloo M, White PJ, Ding Z, Kwok R, Lee P, Radda GK, Toh HC, Hirschey MD, Han W. Loss of BCAA Catabolism during Carcinogenesis Enhances mTORC1 Activity and Promotes Tumor Development and Progression. Cell Metab. 2019 May 7;29(5):1151-1165.e6. doi: 10.1016/j.cmet.2018.12.020. Epub 2019 Jan 17. PMID: 30661928; PMCID: PMC6506390.
Jin Y, Lee WY, Toh ST, Tennakoon C, Toh HC, Chow PK, Chung AY, Chong SS, Ooi LL, Sung WK, Lee CG. Comprehensive analysis of transcriptome profiles in hepatocellular carcinoma. J Transl Med. 2019 Aug 20;17(1):273. doi: 10.1186/s12967-019-2025-x. PMID: 31429776; PMCID: PMC6701074.
Lam JH, Ng HHM, Lim CJ, Sim XN, Malavasi F, Li H, Loh JJH, Sabai K, Kim JK, Ong CCH, Loh T, Leow WQ, Choo SP, Toh HC, Lee SY, Chan CY, Chew V, Lim TS, Yeong J, Lim TKH. Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma. Front Immunol. 2019 Sep 4;10:2093. doi: 10.3389/fimmu.2019.02093. PMID: 31552039; PMCID: PMC6738266.
Ding Z, Ericksen RE, Escande-Beillard N, Lee QY, Loh A, Denil S, Steckel M, Haegebarth A, Wai Ho TS, Chow P, Toh HC, Reversade B, Gruenewald S, Han W. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. J Hepatol. 2020 Apr;72(4):725-735. doi: 10.1016/j.jhep.2019.10.026. Epub 2019 Nov 11. PMID: 31726117.
Tran HTN, Ang KS, Chevrier M, Zhang X, Lee NYS, Goh M, Chen J. A benchmark of batch-effect correction methods for single-cell RNA sequencing data. Genome Biol. 2020 Jan 16;21(1):12. doi: 10.1186/s13059-019-1850-9. PMID: 31948481; PMCID: PMC6964114.
Tai D, Choo SP, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers (Basel). 2019 Dec 3;11(12):1926. doi: 10.3390/cancers11121926. PMID: 31816940; PMCID: PMC6966558.